HEALTH

NEW YORK There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was scuttled after receiving a complete response letter from the Food and Drug Administration.

NEW YORK The business of blood glucose meters has always been a business of “what will they think of next?” When people with diabetes didn’t aggressively test because of the painful, daily pin pricks of their fingertips, manufacturers secured approval for alternate site testing. Manufacturers also developed no-coding meters to eliminate any errors in testing that may have resulted from miscoded testing strips, when that was identified as a potential interface issue.